We conducted an open-label study ofI 09 untreated pati ents who had excessive or impacted cerumen. Our goal was to evaluate the safety and efficacy of Sofen; Cerum enolytic Solution , a methyltrypsin -contaiuing earw ax remova l solution. Each patient 'sexte rnal auditory canal was fill ed with Sofenz.for IS minut es. The prim al)' measure of efficacy-visibility ofthe tympanic membrane-was assessed after the solution had been drain ed fro m the canal and again after the canal had been irrigated with lukewarm water:If the tympanic memb rane was not completely visible fo llowing either appli cation, the procedure was repeated. A safety examination was conducted I to 3 days af ter treatm ent. Seco ndary outcomes measures included relief ofotologic symptoms (e.g., hearing loss, tinnitus, etc.) and patients' overa ll satisfact ion with treatm ent. Immediately after treatment, we f ound that the external audit ory canal was completely visible in 81 patients (74.3 %) after I application of Sofen: and subsequent irrigation, and in 98 pati ents (89.9 %) aft er 2 applications ofeach. At the safety fo llow-up visit, we determine d that the numb er ofotologic symptoms had declined by 93.2%. A self-reported assessment completed by each patient fo llowing the procedure revealed a high degree of satisfaction with treatm ent. A total of58 adve rse events were reported. but only 16 were directly related to treatment, and all were transient and eithertn ild or moderate. We conclude that l or 2 applications ofSofenzfollowed by irrigation with lukewarm water is a safe. well-tolerated. and effective treatment fo r excessive or impa cted cerumen in the external audit ory canal.
Introduction
Excessive and impacted earwax in the external auditory ca nal affec ts up to 6% of the Western popul ation; approximatel y 150,000 earwax remova l procedures are performed each week in the United States. 1. 2 Th e accumulated cerum en is made up of a mixture of keratin debr is and the secretory produ cts of the ceruminou s and sebaceous glands in the extern al auditory canal. [2] [3] [4] Occlus ion ofthe external auditory canal by excessive amounts of cerumen can ca use temporary hearing loss, discomfort , pruritus, tinnitu s, pain, occasion al cough, and dizziness, and it ca n prom ote infection. " Earwax can be remove d mech anically, but patients' routi ne attempts to clean the external auditory canal with cotton-tipped swa bs may actu ally exacerbate ce rumen impa ctio n." Other common method s of earwax remo val, such as syringing and irrigation with dentaljets, may cause serious ear injury, includin g tympan ic membrane rupture and ossicular disrupt ion. !'"'! In light of the hazards of mech anical removal, it is often preferable to use a ceruminolytic agent to soften or dissol ve an impa ction or to loosen it from the tymp an ic membrane. Such treatment fac ilitates the removal of ea rwax by gentle irrigation with water. However, the use of produ cts that require sophisticated instruments to achieve cerumen remova l (e.g., suction and flushing equipment) may limit the ability of many ped iatricians and genera l practitioners to treat such patient s, and they could lead to otic da mage if used incorrectly.1.12Age nts in curre nt use or under evaluation include various formulations of oleic acid polyp eptide compl ex, triethanolamine polypeptid e, carbamide peroxide, olive oil, mineral oil, sodium bicarbonate, acetic acid, and docusate sodium.12-20 Th e efficacy and tolerability of these agent s vary; olive oil has repeatedly been found to be ineffect ive.
We conducted a study of a relatively new cer uminolyt ic: Sofenz Cerumenolytic Soluti on , which has been approved in Europe and is under evaluation in the United Stat es. Sofenz is a methyltr ypsin so lutio n in an aqueo us buffered vehicl e. Alth ough preclini cal toxic ology studies demonstrated that Sofenz ca rries only a minimal risk to the middle ear mucosa, its labelin g incl udes a precaution that it should not be used by patient s who have a perforat ed tympanic membrane.
In this articl e, we describ e our evaluation of the safety and efficacy of Sofen z in the treatm ent of patient s with excessive or impacted ce rumen in the ex terna l auditory canal.
Patients and methods
Patients. Between Sept. 18 and Nov. 22, 200 I, we co nduct ed an open-labe l trial of Sofen z in 109 patients-60 females (55.0 %) and 49 males (45.0%), age d 2 to 93 years (mea n: 56 ± 22)-who had excessive or imp acted cerumen that had ca used a parti al or complete occlusion of at least one ear canal. (We had originally planned to includ e approximately 100 ev aluable pati ent s in this study, a numb er that wa s based on fea sibility rather than on any formal sample-size calculation.) One patient (0.9%) was yo unger than 12 yea rs, 4 patients (3.7%) were age d 12 to 17 years , 57 patient s (52.3 %) were aged 18 to 64 yea rs, and 47 patient s (43 . 1%) were 65 yea rs of age or older. Wh en both ears met the study eligibility cr iteria, the right ear was designated the study ear ; in all , the study ear was the right ear in 70 patient s (64 .2%).
Patients with an y abnormality of the study ear other than impacted ceru me n had been excluded from participation. These condit ions included the presence ofa tympanostom y tube at any time during the previous 12 month s, a nonintact tymp anic membrane, a known or suspec ted ea r infection , mastoiditis or any oth er suppurative noninfectious ear disorder, a struc tura l anomaly of the ex terna l auditory ca nal, otorrhea, and ble edin g. Oth er exc lusion criteria includ ed the use of any ototo pical dru g or earwax-removal product (with the exception of water or physiologic saline) du ring the precedin g 3 da ys, diabete s mell itus, preg nancy, breastfeeding, and inadequ ate contraception.
Intervention. Th e active ingred ient in Sofenz is methyltrypsin (200 Alc on units per ml , cor res ponding to a co ncentration of -0.025% w/v). Th e so lution was package d in a single-use co ntainer with two co mpa rtmen ts, one co ntaining the meth yltr ypsin and the other the vehicle (sodium bicarbonate, glyce rin, and a citrate buffer).
Patients were required to visit the office twice .At the first visit, patients und erw ent a screening and baselin e exa mination , which was fo llowed by treatm ent and a posttreatm ent ex am inatio n. Between I and 3 days later, patients returned or a follow -up assessment of the age nt's safety.
Wh ile undergoin g treatm ent , patients reclined on their side or sat up w ith the head tilted at a 45°angle and the study ear up. The investigator instill ed the recon stitut ed so lution into the ea r ca nal. The so lution was applied unt il it co mpletely filled the ex terna l auditory ca nal; this usuall y req uired I to 2 m l. Th e Sofenz was allowed to remai n in place for 15 minutes. Afterward, eac h patient turn ed ove r and allowed the fluid to drain from the ear. Residual fluid and any debri s were wiped from the outer edge of the ea r canalbut not from the inside. The investigator then inspected 88 the ear, ge ntly irrigated it with lukewarm wa ter, and assessed it aga in. Whe n the initial treatment was unsuccessful in remov ing the occl usion, the inves tiga tor repeated the procedure. W he n a repeat applica tio n was unsuccessful , a treatm ent failure was de cla red and the patient was treated outside the study protocol as appropriate.
Occlusion. Th e investigators rated the degree of occlusio n of the ex terna l auditory ca nal, as determin ed by their ability to see the tym panic memb rane, as either none, mild, moderate, or complete. These determ inations were made at base line and as many as fo ur times subsequently: ( I) after draining the first applica tio n of Sofen z, (2) after the subsequent irrigation , (3) after draining the seco nd appli cati on of Sofen z if perform ed , and (4) after the seco nd irrigation if performed. Th e primary measure of efficacy was visibility of the tym panic membrane following treat ment. T his surrogate outco me was gra ded on a sca le of I to 5: I: Cerumen occlus ion did not impair visibility of the tympanic membrane after I application and drainin g of Sofen z.
2: Cerum en did not impair visibility after I application and draining of Sofen z and I irrigation wit h lukewarm wa ter.
3: Cerum en did not imp air visibility after 2 applications and drainin gs of Sofen z. 4: Cerumen did not impair visibility after 2 applications and drainin gs of Sofen z and 2 irriga tions with lukewarm wate r. 5: Cerum en partiall y or co mpletely impaired vis ibility of the tymp an ic membrane after 2 applications of Sofenz and 2 irrigations.
Clinical outco me sco res of I to 4 we re co nside red to represent a treatment success, and a score of 5 was classified as a treatm ent failure.
Symptoms, Th e investigators also eva luated six otolog ic sy mptoms-( I) hearing loss, (2) aura l fulln ess, (3) ear disco mfort, (4) ear pruritus, (5) tinnitu s, and (6) ea r pain-on a binary sca le (yes/no) at baselin e, after the co mpletion of treatm ent , and at the fo llow-up visit.
Patient satisfaction. Patient satisfac tio n with treatment was assessed imm ediately after trea tme nt on a sca le of I (no satisfac tio n) to 7 (co mplete satisfac tion). Twelve param eters were evaluated: (1) amelioration of hearin g, (2) co ntrol of ear di scomfort , (3) co ntrol of ea r pruritu s, (4) co ntro l of ear pain , (5) co ntrol of di zzin ess, (6) relief of irritability, (7) relie f of anxiety, (8) reli ef of res tlessness, (9) expected effect of treatment on improving leisure activities, ( 10) expected effect of treatmen t on im proving eac h patien t' s family activ ities, ( II) overall co mfort dur ing treatment , and ( 12) Sy mptoms. Otologic symptoms genera lly abated after treatm ent , as determin ed by both posttreatment and follow-up exa minations (table 2). The percentage of patient s with hearing loss decl ined from 63.3% at baseline to 11.0% immediately after treatm ent ; reductions were also see n with regard to aural fullness (from 48 .6 to 7.3%), discomfort (fro m 34.9 to 5.5 %), pruritus (fro m 25.7 to 8.3%), tinnitu s (fro m 2 1.1 to 5.5%), and pain (fro m 8.3 to 3.7%). Further redu ctions were noted at the follow-u p visit.
Patients required a mean of only 1.2 applications (95% co nfidence interv al [CI] : 1.18 to 1.22).
Patient satisfaction. On average, patient s were well satisfied with outcomes in terms of the 12 measured parameters. On the 7-point scale, the mean satisfaction ratings ranged fro m 4.9 to 6.3.
A dverse events. At the baselin e exa mination, we were able to assess the external ea r canal in 58 pat ient s (53 .2%); after trea tment , assessment was possible in alI I09 patients. Erythema was noted in IS of the 58 patient s (25 .9%) at basel ine, in 43 of the 109 patients (39 .4%) posttreatm ent , and in only 9 patients (8.3 %) at the safety foll ow-up . The cor responding figures with regard to edema of the external canal were 7 (12 .1%), 15 (l 3.8%), and I (0.9%). Ob viously, not all cases of erythema and ede ma necessarily represe nted adverse effects of treatment , since these findings were prese nt at baselin e in so me patients.
Immediately after trea tment, the tympan ic membrane could be assessed in 106 patients, and inflammatio n of the tympanic memb rane was see n in 14 of them (13 .2%). However, at the safety follow-up visit, the numb er had fallen to 4 of 109 patient s (3.7%). The position of the tymp anic mem brane was normal in 103 of 106 patients (97.2%) posttherapy and in 108 of 109 patient s (99 .1%) at the safety follow-up visit. No ty mpanic mem bra ne perforation occ urre d.
In all, 32 patients (29.4%) were affec ted by a total of 58 adverse even ts. We determined that only 16 of these adve rse eve nts were related to treatm ent : ca nal eryt hema (n = 4), eard rum edema (n = 3), ear pruritus (n = 3), canal events through out the study period. An adverse eve nt was considered to have occurred when there was ( I) any increase fro m baselin e in otologic symptom score and (2) a clinically sig nificant otologic sy mptom score after treatment in patients whose tympanic memb rane could not be visualized. The inves tigators classified the relationship of adverse eve nts to the Sofe nz applica tion procedure acco rding to five categories: definitely unrelated , unlikely to be related, and poss ibly, probably, or definitely related.
Statistical analysis. All 109 patients were includ ed in the safety and intent-to-treat efficacy analyses; a per-protocol analysis was not performed. The primary statistical objective of this study was to describe the efficacy of Sofenz, and the primary efficacy variable was the degree of occl usion of the auditory ca nal after each appli cation of Sofenz before and after irrigation. Seco ndary efficacy var iables includ ed relief of symptoms and patient satisfaction.
This study was performed in Belgium in compliance with Good Clinical Practice, Declaration of Helsinki, International Co nference on Harmonization (ICH), and Europea n Co mmission (EC) guidelines . All patie nts (or in the case of minors, a parent or legal guardian) provided written infor med consent.
Results
Of the 109 pat ients enrolled in this study, all received at least I app licatio n of Sofenz. However, I patient decided to withdraw before the seco nd application, and this patient was placed in the treatment failure category. A total of 16 patients were invo lved in 19 protocol violations.
Baselin e findin gs. At the baselin e exa mination, all patients presented with occlusion of the external auditory canal. The occ lusion was comple te in 68 patients (62 .4%), moderate in 36 patients (33.0%), and mild in 5 pat ients (4.6%). Hearing loss was presen t in 69 patients (63.3 %), aural fullness in 53 patients (48.6 %), ear discomfort in 38 patients (34 .9%), ear pruritus in 28 patients (25 .7%), tinnitus in 23 patients (2 1.1%), and ear pain in 9 patient s (8.3%). The co nsistency of ceru men was eva luated in all but 5 patients; based on the total popul ation of 109 patients, 26 (23.9%) had soft cerumen, 46 patien ts (42 .2%) had medium-soft to med ium cerumen, and 32 patients (29.4 %) had medium -hard to hard ceru men.
Treatm ent ef fi cacy. Of the 109 patient s, 8 I (74.3%) were successfully treated with only I app licatio n of Sofe nz and irrigation, and 17 others ( 15.6%) were successfully treated after 2 applicatio ns of each (table I) . Overall, treatment was successful in 98 patients (89.9 %), while I I (10. I %) were cons idered to be treatment failures, including the I patient who dropped out of the study after I unsuccessful application. Irrigation increased the success rate of Sofenz application co nsidera bly, after both the first application (from 0.9 to 74.3 %) and the seco nd applicatio n (fro m 77.1 to 89.9 %) .
Treatment success
After 1st application After 1st irrigation After 2nd application After 2nd irrigation edema (n = I), and other ear di sorders (n = 5); mo st of the other adverse events were attributed to the degre e of cerumen imp acti on . Non e of these adve rse events wa s ser ious. M ost of these mild or mod erate eve nts resolved witho ut treatm ent , and their presen ce did not interrupt the progress of the study.
Discussion
The find ings of our study lead us to co ncl ude that Sofen z is safe and well tolerated . The infreque nt, tra nsie nt, and min or local skin irritati on that we observed might have been cau sed by the Sofen z and/or the procedu re or by the cerumen plu g itself. We did not observe any relev ant or serious side effec ts of Sofenz therapy . Thi s wa s not une xpect ed , ho wever, becau se the incidence of se rious complicati on s requiring spec ialist therapy fo llow ing oth er techniques of ea rwax remo va l is estimated to be only 0.1 %.2 1O f co urse, our sa mple size was too sma ll to detect any such risk in this range . In addition to being safe and we ll tolerat ed , I or 2 application s of Sofenz and subse quent irriga tion with lukewarm wa ter were found to be effective in the treatment of excessive or imp acted ceru me n in the externa l auditory can al. Cerumen was successfully rem oved in 98 of 109 patient s (89.9%). It is also import ant to note that otologic symptoms such as hearin g loss, aura l fullness, discom fort , etc . resol ved in mo st patien ts foll owing treatm en t. Thi s indicates that Sofe nz treatm ent con fers a beneficial effect with regard to not only a surrogate endpoi nt (i.e., visibility of the tympan ic membrane), but on clini call y relevant endpoints, as well.
Ou r study shows that it is advantageo us to irrigate the external auditory cana l with lukewarm wa ter following Sofen z application rathe r than ju st allowing the so lution to dr ain fro m the ear. Our success rate increased co nsiderabl y after irrigati on-from 0.9 to 74.3 % after the first irrigat ion and from 77 . 1 to 89.9% afte r the second. Th is findin g suggests that Sofen z does not full y dissolv e the cerumen plu g; rather, it softens and loosens the plug, thereby making it vulnera ble to ge ntle irrigation . Also, irriga tion appea rs to be necessary to remo ve resid ual meth yltrypsin Volume 85, Number 2 fro m the external aud itory canal , the reb y redu cing the ris k of skin irritation.
Our study sho ws that Sofen z compares favora bly with other subs tances used to remove ceru men as tested in tw o other studies :
• Sin ger et al evaluated the ce ru minolytic effec t of docusate sodium and triethanolamine polypeptide.'? Th e endpoint was tympanic mem bran e visua lization foll owing dru g applicatio n, irriga tion, and add itional mean s if drugs and irrigat ion were not effecti ve. Th ese researc he rs fo und that docu sate sodium was successful in 81% of cases and triethanolam ine polypeptide oleate condensa te wa s effec tive in 35%; ne ither was as effe ctive as Sofenz and irrigation (89.9%) in our study.
• Eekh of et al co mpared syring ing after nightly applications of oil over 3 days and syring ing after application of wat er drops fo r IS minut es.IS Th eir endpoint was the mean number of syringing atte mpts required to rem ove a ceru men plu g (6 attempts represented a treatment failu re). Th ey rep orted that the mean number of attempts wa s 2.4 in the oil group (95% CI: 1.7 to 3. 1) and 3.0 in the wa ter gro up (95% CI : 2.4 to 3.6). Our pati ents fared better than both gro ups in that they required a mean of only 1.2 applications (95% CI : U 8 to 1.22).
In conc lus ion, we found that I or 2 applic ations of Sofen z to the ex ternal auditory cana l over IS minutes, followed by ge ntle irriga tion with lukewarm water, is a safe , well-tolerated , and effecti ve meth od of treatin g excessive and imp acted cerumen in the extern al auditory canal.
